# Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

> **NCT04521140** · PHASE4 · COMPLETED · sponsor: **Nicole Fram M.D.** · enrollment: 36 (actual)

## Conditions studied

- Corneal Edema
- Corneal Defect
- Corneal Transplant
- Penetrating KeratoPlasty
- Anterior Chamber Inflammation
- Ocular Pain
- Intraocular Pressure

## Interventions

- **DRUG:** Dextenza 0.4Mg Ophthalmic Insert
- **DRUG:** Prednisolone Acetate 1% Oph Susp

## Key facts

- **NCT ID:** NCT04521140
- **Lead sponsor:** Nicole Fram M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2023-01-04
- **Final completion:** 2023-01-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521140, "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04521140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*